A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn's Disease
Latest Information Update: 27 Jun 2025
At a glance
- Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms I6T-MC-AMAZ; SHINE-ON
- Sponsors Eli Lilly and Company
Most Recent Events
- 18 Apr 2025 Planned End Date changed from 1 Jul 2030 to 1 Dec 2030.
- 18 Apr 2025 Planned primary completion date changed from 1 Jul 2030 to 1 Dec 2030.
- 03 Dec 2024 Planned End Date changed from 30 Jul 2030 to 1 Jul 2030.